{
    "clinical_study": {
        "@rank": "30370", 
        "brief_summary": {
            "textblock": "The purpose of the study is to select the dose regimen of CDC-501 that provides the most\n      promising evidence of efficacy."
        }, 
        "brief_title": "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "December 2004", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum\n             and/or urine), and be considered to have disease progression after at least two\n             cycles of treatment or have relapsed after treatment.\n\n          -  Subject must understand and voluntarily sign an informed consent document.\n\n          -  Subject must not have received corticosteroids, other chemotherapy, thalidomide, or\n             other investigational agents, within 21 days of baseline\n\n          -  ECOG (Zubrod) performance status of 0 to 2.\n\n          -  Subject must be able to adhere to the study visit schedule and other protocol\n             requirements.\n\n          -  Women of childbearing potential (WCBP ) must have a negative serum or urine pregnancy\n             test within 7 days of baseline.  In addition, sexually active WCBP must agree to use\n             adequate contraceptive methods (oral, injectable, or implantable hormonal\n             contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with\n             spermicide; or vasectomized partner) while on study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 16, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00044018", 
            "org_study_id": "CC-5013-MM-007"
        }, 
        "intervention": {
            "intervention_name": "CDC-501", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Lenalidomide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Revimid", 
            "CC5013"
        ], 
        "lastchanged_date": "September 22, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H Lee Moffit Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55902"
                    }, 
                    "name": "Mayo Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "St Vincent's Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Robert Knight, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00044018"
        }, 
        "responsible_party": {
            "name_title": "Robert Knight MD - VP Hematology", 
            "organization": "Celgene Corporation"
        }, 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2009"
    }, 
    "geocoordinates": {
        "Dana-Farber Cancer Institute": "42.358 -71.06", 
        "H Lee Moffit Cancer Center": "27.951 -82.457", 
        "Mayo Clinic": "44.022 -92.47", 
        "St Vincent's Cancer Center": "40.714 -74.006"
    }
}